Health Canada grants priority review status to trifluridine and tipiracil for refractory metastatic colorectal cancer


Friday, 20 Oct 2017 

Oct 20 (Reuters) - Otsuka Holdings Co Ltd :Taiho Pharma Canada - Health Canada accepted for review new drug submission for trifluridine, tipiracil,NDS granted priority review status​.Taiho Pharma Canada - Health Canada's review of NDS under priority review is expected to be completed in early 2018​. 

Source : https://in.reuters.com/finance/stocks/4578.T/key-developments/article/3690990

Related Posts